The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib +Programmed Cell Death Protein 1 (PD-1) Antibody in the Conversion-resection of Advanced Unresectable Hepatocellular Carcinoma:a Multicenter Prospective Cohort Study
Sponsor: Xinrui Zhu，MD
This PHASE1/PHASE2 trial investigates Hepatocellular Carcinoma Non-resectable and Immune Checkpoint Blockade and is currently completed. Xinrui Zhu，MD leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Unknown → Completed
-
Jan 2025 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
Status: Enrolling By Invitation → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Enrolling By Invitation PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Enrolling By Invitation PHASE1_PHASE2
▶ Show 1 earlier version
-
Sep 2021 — Jun 2022 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Xinrui Zhu，MD
For direct contact, visit the study record on ClinicalTrials.gov .